annual meeting program - American Society of Clinical Oncology

Saturday, June 5, 2010
Brd. 25G Phase I/II study of sunitinib (SU) in combination with metronomic dosing of
cyclophosphamide (C) and methotrexate (M) in patients (pts) with metastatic
breast cancer (MBC). (Abstract #1067)
A. J. Chien, J. Aicardi, M. E. Melisko, A. Goga, M. M. Moasser, J. W. Park,
P. N. Munster, H. S. Rugo
Brd. 25H Free methylated DNA in association of clinical signs and circulating blood
tumor cells in patients with breast cancer. (Abstract #1068)
C. Matuschek, E. Boelke, W. Budach, H. Prisack, H. Taskin, M. Peiper, M. Rezai,
H. Bojar
Brd. 26A Survival benefit of neck dissection for patients with breast cancer with
supraclavicular lymph node metastasis. (Abstract #1069)
S. Chen
Brd. 26B Incorporation of a comprehensive geriatric assessment (CGA) into a
randomized phase III trial for metastatic breast cancer (MBC): The PELICAN
study. (Abstract #1070)
M. De Wit, F. Honecker, U. Wedding, D. Waldenmaier, J. Dorn, M. Warm,
S. Al-Batran, M. Schmidt, R. Kreienberg, N. Harbeck
Brd. 26F The comparison of the benefits obtained from platinum-containing
chemotherapy between triple-negative and non-triple-negative metastatic
breast cancer. (Abstract #1071)
T. Kim, H. Lee, S. Han, D. Oh, S. Im, Y. Bang
Brd. 26G Addition of BIBW 2992, an irreversible inhibitor of EGFR/HER1 and HER2, to
letrozole in estrogen receptor (ER)-positive metastatic breast cancer (mBC)
progressing on letrozole monotherapy. (Abstract #1072)
K. Gunzer, H. de Mont-Serrat, M. M. Uttenreuther-Fischer, J. Misset, on behalf of
study group and trial team
Brd. 26H Multivariate analysis (MVA) of progression-free survival (PFS) in two phase
IIb, multinational, double-blind, randomized, placebo (PL)-controlled trials
evaluating sorafenib (SOR) plus standard chemotherapy in patients (pts)
with HER2-negative locally advanced or metastatic breast cancer (BC).
(Abstract #1073)
W. J. Gradishar, F. Dalenc, V. G. Kaklamani, F. Costa, T. P. Sahoo, J. Segalla,
D. Lokanatha, H. Pinczowski, V. Raina, J. Baselga
Brd. 27A A phase II study of medroxyprogesterone acetate (MPA) in patients (pts) with
hormone receptor-negative (HR-) metastatic breast cancer (MBC):
Translational Breast Cancer Research Consortium trial 007. (Abstract #1074)
L. G. Vaughn, L. Li, L. Nabell, H. S. Rugo, L. A. Carey, G. G. Kimmick, P. S. Steeg,
K. Miller
Brd. 27B Breast cancer metastasis gene signature: The search for the holy grail.
(Abstract #1075)
R. E. Ellsworth, L. A. Field, B. Love, J. L. Kane, J. A. Hooke, C. D. Shriver
Brd. 27C Effect of the novel oncomir MiR-301 on tumor proliferation and invasion in
human breast cancer. (Abstract #1076)
W. Shi, K. Gerster, N. Alajez, J. Tsang, L. Waldron, M. Pintilie, A. Hui,
D. R. McCready, A. W. Fyles, N. Miller, F. F. Liu
Brd. 27D Phase II study of the combination of oral vinorelbine (NVBo), capecitabine
(X), and trastuzumab (H) in HER2-positive, metastatic breast cancer (MBC):
Recent analysis of the results with a median follow-up of 44 months.
(Abstract #1077)
L. B. Petruzelka, V. Ganju, D. Becquart, P. F. Conte, N. Tubiana-Mathieu, M. J. Gil
Gil, M. Morand, N. Vaissiere, G. Villanova, A. Chan
Brd. 27E Genetic signature of breast cancer with lymphangitic spread to the chest
wall: Results from a randomized phase II study combining bevacizumab with
oral vinorelbine plus capecitabine (BEVIX). (Abstract #1078)
G. Curigliano, M. Alkalay, M. A. Locatelli, L. Fumagalli, S. Giudici, F. Bertolini,
V. Galimberti, G. Viale, F. Nole, A. Goldhirsch
161
SATURDAY